BridgeBio rises on FDA priority review for dwarfism drug
BUZZ-BridgeBio rises on FDA priority review for dwarfism drug ** Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.5% to $67.80 premarket
** Co says US FDA grants priority review to its application seeking approval of experimental oral drug infigratinib for children with achondroplasia, the most common form of dwarfism
** FDA sets Feb. 4, 2027, as target date for its decision
** Application is backed by a late-stage study that met its main and key secondary goals; children treated with infigratinib grew an adjusted 1.74 cm per year faster than those given placebo
** Drug also improved arm span, as well as body proportions among children younger than eight; no serious side effects linked to the drug or treatment-related discontinuations were reported
** BridgeBio plans to seek European approval in Q4 2026
** As of last close, BBIO down 13.5% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels